|
|
Volumn 52, Issue 2, 2012, Pages 145-147
|
|
Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BCR ABL PROTEIN;
BENZAMIDE DERIVATIVE;
DASATINIB;
IMATINIB;
JAK2 PROTEIN, HUMAN;
JANUS KINASE 2;
PIPERAZINE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
THIAZOLE DERIVATIVE;
ADULT;
CASE REPORT;
CHRONIC MYELOID LEUKEMIA;
DRUG RESISTANCE;
GENE TRANSLOCATION;
GENETICS;
HEMATOPOIETIC STEM CELL;
HUMAN;
LETTER;
MALE;
MUTATION;
PATHOLOGY;
ADULT;
ANTINEOPLASTIC AGENTS;
BENZAMIDES;
DRUG RESISTANCE, NEOPLASM;
FUSION PROTEINS, BCR-ABL;
HEMATOPOIETIC STEM CELLS;
HUMANS;
JANUS KINASE 2;
LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;
MALE;
MUTATION;
PIPERAZINES;
PYRIMIDINES;
THIAZOLES;
TRANSLOCATION, GENETIC;
|
|
EID: 84877307651
PISSN: None
EISSN: 18809952
Source Type: Journal
DOI: 10.3960/jslrt.52.145 Document Type: Letter |
|
Times cited : (12)
|
|
References (0)
|
